Very recently, the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended that burosumab be approved for the treatment of FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in children and adolescents aged 1 to 17 years and in adults [74,75,76]. Here, FGF23 is linked to hypophosphatemia.